Vitamin B12: treat deficiency early—neurological injury can occur even without anaemia
Vitamin B12 (cobalamin) is essential for DNA synthesis, myelin integrity and red-cell maturation. Deficiency may cause megaloblastic anaemia, glossitis and neuropsychiatric disease. The defining clinical difference from folate deficiency is that B12 deficiency can cause progressive neuropathy and spinal-cord injury; never wait for macrocytosis before considering it.
Learning outcomes
Explain intrinsic-factor dependent absorption, identify dietary and malabsorptive causes, distinguish B12 from folate deficiency, interpret the core investigation pathway, choose oral versus parenteral replacement principles, and monitor neurological recovery safely.
1. The one-minute clinical map
| Question | Answer |
|---|---|
| What is B12? | A water-soluble cobalamin obtained from animal-source foods or supplements; body stores can delay presentation for years. |
| Where is it absorbed? | Terminal ileum after binding to intrinsic factor produced by gastric parietal cells. |
| Why does it matter? | DNA synthesis, methionine synthase, methylmalonyl-CoA metabolism and neurological myelin maintenance. |
| Key danger? | Neurological damage—paresthesia, sensory ataxia, gait or cognitive change—may occur with a normal Hb/MCV. |
| Core treatment principle? | Replace promptly using a cause-appropriate oral or IM regimen; manage the underlying cause and monitor response. |
2. Absorption and pharmacology
Release and binding
Food B12 is released in the stomach, binds salivary haptocorrin, then after pancreatic digestion binds intrinsic factor (IF).
Terminal ileum
The IF–B12 complex is taken up in the terminal ileum. It travels in blood on transcobalamin to tissues and is stored mainly in liver.
Metabolic reactions
B12 supports methionine synthase (folate recycling/homocysteine metabolism) and methylmalonyl-CoA mutase. Deficiency raises homocysteine and methylmalonic acid (MMA).
Clinical link: autoimmune destruction of parietal cells or intrinsic factor causes pernicious anaemia; ileal disease/resection prevents normal uptake. In these situations diet alone will not correct the problem.
3. Causes and risk groups
| Cause | Examples | Clinical implication |
|---|---|---|
| Autoimmune malabsorption | Pernicious anaemia/autoimmune gastritis | Intrinsic-factor failure; usually long-term replacement and review for associated autoimmune disease as locally indicated. |
| Gastric causes | Gastrectomy, bariatric surgery, chronic atrophic gastritis | Reduced acid/IF handling; assess lifelong risk. |
| Ileal/pancreatic causes | Crohn disease, terminal-ileal resection, coeliac disease, bacterial overgrowth, pancreatic insufficiency | Absorption may be unreliable; parenteral therapy may be required. |
| Low intake | Strict vegan diet without supplementation, food insecurity, frailty | Dietary replacement may succeed if absorption is intact, but assess severity and adherence. |
| Medicine-related | Metformin, acid-suppressing therapy and others in susceptible patients | Review duration, symptoms and alternative causes; do not stop essential medicines without a clinician. |
4. Presentation: anaemia plus the nervous system
- Haematological: fatigue, pallor, exertional dyspnoea, macrocytosis, glossitis, mouth ulcers; severe cases may have leukopenia or thrombocytopenia.
- Neurological: numbness/tingling, loss of vibration or position sense, gait imbalance, weakness, visual change and subacute combined cord disease.
- Neuropsychiatric: poor concentration, memory change, depression, irritability, psychosis or cognitive decline.
- Paediatric: poor growth, developmental delay or regression in severe deficiency.
B12 versus folate deficiency
Both cause megaloblastic anaemia and high homocysteine. MMA rises in B12 deficiency, not isolated folate deficiency. Folate can improve the blood count in a B12-deficient patient but cannot protect the nervous system—so test and treat B12 when there is uncertainty.
5. Diagnosis: tests and interpretation
| Assessment | Use |
|---|---|
| FBC and film | Macrocytosis, macro-ovalocytes, hypersegmented neutrophils; a normal MCV does not exclude B12 deficiency if iron deficiency or thalassaemia coexist. |
| Serum B12 | Initial biochemical test; interpret borderline values with symptoms, medicines and assay limitations. |
| MMA ± homocysteine | Helpful for uncertain cases. MMA is more specific for B12 deficiency but can be raised in renal impairment. |
| Anti-intrinsic-factor antibodies | Supports pernicious anaemia/autoimmune cause when clinically appropriate. |
| Cause investigation | Diet, alcohol, drug and surgical history; assess gastric/ileal disease, coeliac disease and other malabsorption risks. |
Urgent escalation: new gait disorder, rapidly progressive sensory loss, severe weakness, cognitive change, severe anaemia or pancytopenia needs urgent senior/specialist assessment and prompt replacement—not routine delayed follow-up.
6. Replacement: formulation and route principles
Oral cyanocobalamin
Can be appropriate for dietary deficiency and selected patients with intact or sufficient absorption, using the local guideline and reliable follow-up. High oral doses may still be absorbed passively in some malabsorptive states, but this is a cause-specific clinical decision.
IM hydroxocobalamin
Commonly used where deficiency is due to malabsorption, pernicious anaemia, significant symptoms or neurological involvement. Loading and maintenance schedules vary by guideline, product and cause. NICE-based pathways commonly use 1 mg IM three times weekly for two weeks when no neurological involvement; neurological symptoms require more urgent/specialist-led regimens. Do not copy a schedule blindly—apply the local protocol.
Maintenance
Non-diet-related irreversible malabsorption often needs lifelong replacement; diet-related deficiency may allow oral maintenance after stores are restored. Review the cause before deciding that injections can stop.
7. Monitoring and expected response
| Stage | Check | Interpretation |
|---|---|---|
| Baseline | Symptoms, neurological examination, FBC, B12 ± MMA, cause assessment | Record deficits before treatment; do not let a single normal-looking MCV overrule the story. |
| Early response | Reticulocyte response and symptomatic change may be seen within days to weeks | Failure suggests wrong diagnosis, mixed deficiency, non-adherence, wrong route or ongoing pathology. |
| Follow-up | FBC/MCV recovery and neurological review | Haematology often corrects before nerves; neurological recovery may be incomplete if treatment is late. |
| Long-term | Adherence, injection schedule/oral supply, recurrent symptoms and cause-specific review | Lifelong risk requires a clear follow-up plan. |
8. Adverse effects and counselling
Vitamin B12 replacement is usually well tolerated. Injection-site reactions, headache, nausea, rash or rarely hypersensitivity can occur. Explain that hydroxocobalamin may discolour urine pink/red temporarily. Counsel patients to report worsening weakness, gait change, numbness, breathlessness, chest pain or severe allergic symptoms. Dietary improvement is valuable, but it cannot replace injections where intrinsic factor or ileal absorption is absent.
9. Cases for exams and wards
Case 1 — “normal Hb” does not rule it out
A patient with metformin exposure reports progressive tingling and impaired vibration sense; Hb and MCV are normal. B12 deficiency remains possible. Investigate and treat promptly if confirmed; do not wait for macrocytic anaemia.
Case 2 — pernicious anaemia
A patient has macrocytosis, low B12 and positive intrinsic-factor antibody. Explain the absorption defect, initiate cause-appropriate replacement, record neurological status and plan long-term maintenance rather than repeated short courses.
Case 3 — folate trap
A macrocytic patient was given folic acid and the Hb improved, but gait has worsened. This does not exclude B12 deficiency; assess urgently and treat B12 as indicated.
10. Exam-ready summary
- B12 is absorbed in terminal ileum only after binding intrinsic factor.
- Pernicious anaemia is an autoimmune cause of B12 malabsorption.
- Neurological disease can occur without anaemia.
- B12 and folate deficiency both raise homocysteine; MMA points to B12.
- Folic acid can mask haematological B12 deficiency but does not prevent neurological progression.
- Route and maintenance depend on cause—not merely the serum value.
11. Further study and sources
- Course reference: Vitamin B12, folic acid and megaloblastic anaemias.
- NICE: Vitamin B12 deficiency in over 16s: diagnosis and management.
- MedlinePlus: Vitamin B12 deficiency anaemia.
- NHS: B12 or folate deficiency anaemia treatment.
- NIH ODS: Vitamin B12 fact sheet.
Educational resource: use current national guidelines, local formulary information and senior clinical supervision for individual patients.
